Immunicum AB (DE:1YG0)
FRANKFURT:1YG0
Germany Market
Holding DE:1YG0?
Track your performance easily

Immunicum AB (1YG0) Income Statement

1 Followers

Immunicum AB Income Statement

Last quarter (Q3 2022), Immunicum AB's total revenue was kr0.00, a decrease of ― from the same quarter last year. In Q3, Immunicum AB's net income was kr-38.60M. See Immunicum AB’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
kr 1.79Mkr 0.00kr 0.00kr 0.00kr 0.00kr 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
kr 125.07Mkr 129.28Mkr 85.96Mkr 44.87Mkr 96.54Mkr 80.70M
Operating Income
kr -123.28Mkr -129.28Mkr -85.96Mkr -44.87Mkr -96.54Mkr -80.70M
Net Non Operating Interest Income Expense
kr -4.22Mkr -3.28Mkr -3.22Mkr -2.92Mkr -14.00Kkr -273.00K
Other Income Expense
------
Pretax Income
kr -128.35Mkr -133.41Mkr -89.25Mkr -47.77Mkr -97.86Mkr -80.34M
Tax Provision
-kr 0.00kr 0.00kr 0.00kr 0.00kr 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
kr -128.35Mkr -133.41Mkr -89.25Mkr -47.77Mkr -97.86Mkr -80.34M
Basic EPS
kr -0.48kr -0.73----
Diluted EPS
kr -0.48kr -0.73----
Basic Average Shares
kr 595.65Mkr 183.98M----
Diluted Average Shares
kr 595.65Mkr 183.98M----
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
-----kr 1.10M
Total Expenses
kr 125.07Mkr 129.28Mkr 85.96Mkr 44.87Mkr 96.54Mkr 80.70M
Net Income From Continuing And Discontinued Operation
kr -128.35Mkr -133.41Mkr -89.25Mkr -47.77Mkr -97.86Mkr -80.34M
Normalized Income
kr -128.35Mkr -133.41Mkr -89.25Mkr -47.77Mkr -97.86Mkr -80.97M
Interest Expense
kr 4.45Mkr 3.28Mkr 3.22Mkr 2.92Mkr 14.00Kkr 273.00K
EBIT
kr -123.90Mkr -130.13Mkr -86.03Mkr -44.86Mkr -97.85Mkr -80.06M
EBITDA
kr -122.40Mkr -128.28Mkr -84.25Mkr -44.86Mkr -97.85Mkr -80.06M
Currency in SEK

Immunicum AB Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis